High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples